Clinical Trial Update: Study Of Adjuvant Lapatinib In High-Risk Head And Neck Cancer Subjects After Surgery [Phase 3]

View source ↗

Summary

Phase 3 trial update for adjuvant lapatinib after surgery in high-risk head and neck cancer; the study is completed and results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Cancer

Drugs mentioned

• Lapatinib (Lapatinib)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Neoplasms, Head and Neck | Phase 3 | Status: COMPLETED | Results posted: 2014-02-11